Last updated on May 2018

A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

Brief description of study

PIONEER-II OPC trial is a prospective, multicenter, single-arm registry trial. 1000 subjects from approximately 40 interventional cardiology centers will be enrolled to evaluate the target lesion failure(TLF) as the primary endpoint at 1 year. And all the subjects will be followed up to 5 years to attain the data of the secondary endpoints.

Detailed Study Description

Realizing even more uniform and complete endothelial coverage, BuMA Supreme biodegradable drug coating coronary stent system comprises a new generation of biodegradable drug eluting stent under development by Sino medical science(SINOMED). BuMA Supreme reconfigures BuMA DES utilizing a high caliber cobalt chromium platform coated with rapidly degrading PLGA scaffold.

Clinical Study Identifier: NCT02698852

Contact Investigators or Research Sites near you

Start Over

Junbo Ge, Ph.D

Zhongshan Hospital
Shanghai, China